Nipah virus vaccine enters Phase I trial - European Pharmaceutical Review

7/13/2022 12:00:00 AM2 years 9 months ago

The mRNA-1215 vaccine for Nipah virus – a disease of pandemic potential, will be evaluated for safety, tolerability and immunogenicity.

Posted: 13 July 2022 | Hannah Balfour (European Pharmaceutical Review) | No comments yet The investigational mRNA-1215 vaccine developed to prevent Nipah virus a bat-borne disease of pandemic potent… [+2950 chars]

full article...